文献速递肝病消化道肿瘤与早癌消化内镜

美国肝病研究学会实践指标委员会制定肝硬化质量指标

Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
PubMed 文献 · Hepatology · 2019-03-12

美国肝病研究学会实践指标委员会通过文献综述、专家临床医生和患者焦点小组输入,采用改良德尔菲法由11名专家临床医生小组从119项候选指标中确定46项肝硬化质量指标,包括26项过程指标、7项临床结局指标和13项患者报告结局指标,并在美国9家机构的79例肝硬化患者中验证了患者报告结局指标。

要点

  • 从119项候选指标中确定46项肝硬化质量指标,含26项过程指标、7项临床结局指标和13项患者报告结局指标。
  • 过程指标覆盖腹水(n=5)、静脉曲张/出血(n=7)、肝性脑病(n=4)、肝细胞癌筛查(n=1)、肝移植评估(n=2)和其他照护(n=7)。
  • 患者报告结局指标在美国9家机构的79例肝硬化患者中验证。

核心结论

  • 制定了针对成人肝硬化患者的一套明确的循证质量指标,供提供者和机构评估照护质量、推动质量改进并提供高价值肝硬化照护,旨在适用于任何提供肝硬化患者照护的临床照护环境。

研究设计与样本

  • 美国肝病研究学会实践指标委员会通过全面文献综述、专家临床医生和患者焦点小组输入确定候选指标,并采用11名专家临床医生小组的改良德尔菲法系统识别肝硬化质量指标。

主要发现

  • 在119项候选指标中,46项被确定为定义肝硬化照护质量的重要指标,包括26项过程指标、7项临床结局指标和13项患者报告结局指标。
  • 过程指标覆盖腹水(n=5)、静脉曲张/出血(n=7)、肝性脑病(n=4)、肝细胞癌筛查(n=1)、肝移植评估(n=2)和其他照护(n=7)。
  • 临床结局指标包括生存、静脉曲张出血和再出血、早期肝细胞癌、肝脏相关住院以及7天和30天内再住院。
  • 患者报告结局指标覆盖躯体症状、躯体功能、心理健康、一般功能、认知、社交生活和照护满意度。
  • 最终患者报告结局列表在美国9家机构的79例肝硬化患者中验证。

关键数值与推荐

  • 从119项候选指标中确定46项重要质量指标,包括26项过程指标、7项临床结局指标和13项患者报告结局指标。
  • 过程指标:腹水n=5、静脉曲张/出血n=7、肝性脑病n=4、肝细胞癌筛查n=1、肝移植评估n=2、其他照护n=7。
  • 临床结局指标包括生存、静脉曲张出血和再出血、早期肝细胞癌、肝脏相关住院以及7天和30天内再住院。
  • 患者报告结局指标覆盖躯体症状、躯体功能、心理健康、一般功能、认知、社交生活和照护满意度,并在美国9家机构的79例肝硬化患者中验证。

临床怎么用

  • 这些质量指标是提供者和机构评估照护质量、推动质量改进并提供高价值肝硬化照护的工具。
  • 这些质量指标旨在适用于任何提供肝硬化患者照护的临床照护环境。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Health care delivery is increasingly evaluated according to quality measures, yet such measures are underdeveloped for cirrhosis. The Practice Metrics Committee of the American Association for the Study of Liver Diseases was charged with developing explicit process-based and outcome-based measures for adults with cirrhosis. We identified candidate measures from comprehensive reviews of the literature and input from expert clinicians and patient focus groups. We conducted an 11-member expert clinician panel and used a modified Delphi method to systematically identify a set of quality measures in cirrhosis. Among 119 candidate measures, 46 were identified as important measures to define the quality of cirrhosis care, including 26 process measures, 7 clinical outcome measures, and 13 patient-reported outcome measures. The final process measures captured care processes for ascites (n = 5), varices/bleeding (n = 7), hepatic encephalopathy (n = 4), hepatocellular cancer (HCC) screening (n = 1), liver transplantation evaluation (n = 2), and other care (n = 7). Clinical outcome measures included survival, variceal bleeding and rebleeding, early-stage HCC, liver-related hospitalization, and rehospitalization within 7 and 30 days. Patient-reported outcome measures covered physical symptoms, physical function, mental health, general function, cognition, social life, and satisfaction with care. The final list of patient-reported outcomes was validated in 79 patients with cirrhosis from nine institutions in the United States. Conclusion: We developed an explicit set of evidence-based quality measures for adult patients with cirrhosis. These measures are a tool for providers and institutions to evaluate their care quality, drive quality improvement, and deliver high-value cirrhosis care. The quality measures are intended to be applicable in any clinical care setting in which care for patients with cirrhosis is provided.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kanwal F, Tapper EB, Ho C, et al. Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2019. PMID: 30586188. doi:10.1002/hep.30489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。